Related Experiment Video
Updated: Jul 13, 2026
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
[Pneumocystis pneumonia in newborns: a challenge in contemporary intensive care]
Agnieszka Kordek1, Lidia Kołodziejczyk, Beata Pawlus
1Katedra Połoznictwa, Ginekologii i Neonatologii Pomorskiej Akademii Medycznej, Szczecin.
Insights
Pneumocystis pneumonia (PCP) is caused by Pneumocystis jiroveci, a fungus affecting immunocompromised individuals, including premature infants. This paper details PCP symptoms, diagnosis, and treatment in infants.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pediatric Critical Care
Background:
- Pneumocystis jiroveci (P. jiroveci) causes Pneumocystis pneumonia (PCP) in immunocompromised patients.
- Rising incidence of immunosuppression (AIDS, chemotherapy, organ transplant) increases clinical interest in P. jiroveci.
- Premature, critically ill infants in ICUs are a vulnerable population for P. jiroveci infection.
Purpose of the Study:
- To review the clinical manifestations of PCP in infants.
- To outline current diagnostic strategies for PCP in this age group.
- To describe established treatment protocols for infant PCP.
Main Methods:
- Review of clinical literature on Pneumocystis jiroveci and Pneumocystis pneumonia in infants.
- Analysis of diagnostic methods for PCP.
- Summary of current treatment guidelines for PCP.
Main Results:
- P. jiroveci is an opportunistic fungus with specific human host.
- Infants, particularly premature and critically ill, are at risk.
- Molecular biology advances have clarified pathogen taxonomy and PCP pathogenesis.
Conclusions:
- PCP is a significant opportunistic infection in immunocompromised infants.
- Accurate diagnosis and timely treatment are crucial for managing PCP in infants.
- Understanding P. jiroveci's characteristics aids in managing this infection.
Abstract:
Pneumocystis jiroveci (P. jiroveci) is the etiological agent of pneumocystis pneumonia (PCP) in immunodeficient patients. The increased interest of clinicians in this particular pathogen during the past decade was prompted by rising numbers of patients with immunosuppression caused by AIDS, chemotherapy, or organ transplantation. Premature, seriously ill infants at intensive care units constitute a potential risk group for infection with P. jiroveci. Recent advances in medical sciences, owing mainly to developments in molecular biology, permitted the verification of the taxonomic position of pathogens and contributed to a better understanding of new aspects of pathophysiology and pathogenesis of PCP. It has been demonstrated that the genus Pneumocystis represents a heterogeneous group of opportunistic fungi exhibiting narrow host specificity. Pneumocystis jiroveci is the species which is specific for humans. The present paper outlines the clinical symptoms of PCP in infants, currently used diagnostic methods, and treatment procedures in PCP.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology